Laboratory Corporation of America Holdings (LabCorp) and Chiltern announced today that they have entered into a definitive agreement under which LabCorp will acquire Chiltern in an all-cash transaction valued at approximately $1.2bn. Upon completion of the transaction, Chiltern will become part of LabCorp’s Covance Drug Development segment.